Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A microRNA-135b mimic is a synthetic, double-stranded RNA oligonucleotide designed to simulate the biological activity of the endogenous microRNA miR-135b. In the context of colorectal cancer (CRC) research, miR-135b has been identified as an oncomiR that promotes cell survival and chemoresistance. The mimic is used to overexpress miR-135b, which directly targets and downregulates the tumor suppressor Large Tumor Suppressor Kinase 2 (LATS2). This downregulation leads to the inhibition of apoptosis and increases resistance to chemotherapeutic agents like doxorubicin. While the mimic itself is primarily a research tool used to elucidate the miR-135b/LATS2 signaling axis, the inhibition of this axis is considered a potential therapeutic target for CRC.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-135b mimic.